Skip to main content

Table 1 Comparison of patients’ demographic and clinical features at baseline and after the end of the trial between the two groups

From: Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial

Variables Topiramate (n) Metformin (n) χ2/t P value
n 32 30  
Gender (M1/F) 28/4 24/6 0.64 > 0.05
Age (years) 32.81 ± 9.11 31.87 ± 8.48 0.42 > 0.05
Marital status (M2/S1/D) 9 /22 /1 11 /16 /3 2.09 > 0.05
Occupation (F/J/E) 15 /13 /4 16 /8 /6 1.56 > 0.05
Level of education     
 Primary education 15 13 0.44 > 0.05
 Secondary education 15 16   
 College and above 2 1   
Parental obesity     
 No/yes 29/3 28/2 0.15 > 0.05
Diagnosis (S2/AD) 31/1 27/3 1.21 > 0.05
Inpatients/outpatients 2/30 0/30 1.94 > 0.05
The number of patients with/without loss of follow-up
 With/without loss of follow-up at week 4 5/27 10/20 2.65 > 0.05
 With/without loss of follow-up at week 8 6/26 11/19 2.50 > 0.05
 With/without loss of follow-up at week 12 15/17 13/17 0.08 > 0.05
 With/without loss of follow-up at week 16 22/10 15/15 2.26 > 0.05
CPZ equivalent daily dose of all APS used during the trial 433.75 ± 215.57 370.17 ± 177.07 1.26 > 0.05
The main types of APS currently in use during the trial
 Clozapine 16 10 3.15 > 0.05
 Olanzapine 6 6   
 Quetiapine 2 5   
 Risperidone 4 6   
 Other APS, and etc. 4 3   
Daily dosage of clozapine during the trial (n: 16, 10) 229.69 ± 121.18 165 ± 114.99 1.35 > 0.05
Daily dosage of olanzapine during the trial (n: 6, 6) 10.0 ± 6.32 12.08 ± 5.10 0.63 > 0.05
  1. M1 male, M2 married, S1 single, D divorced, F farmer, J jobless, E employee, S2 schizophrenia, AD affective disorder, CPZ chlorpromazine, APS antipsychotics